Literature DB >> 20855462

Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.

Tong Sun1, Gwo-Shu Mary Lee, William K Oh, Mark Pomerantz, Ming Yang, Wanling Xie, Matthew L Freedman, Philip W Kantoff.   

Abstract

PURPOSE: The tumor suppressor p53 plays a crucial role in maintaining genomic stability and tumor prevention. Mdm2, Mdm4, and Hausp are all critical regulators of the p53 protein. Despite the importance of the p53 pathway in prostate cancer development and progression, little is known about the association of functional single-nucleotide polymorphisms (SNP) in the p53 pathway genes and prostate cancer aggressiveness. EXPERIMENTAL
DESIGN: In this study, we analyze the association of SNPs in p53, Mdm2, Mdm4, and Hausp genes with prostate cancer clinicopathologic variables in a large hospital-based Caucasian prostate cancer cohort (N = 4,073).
RESULTS: We found that the Mdm2 SNP309 T allele was associated with earlier onset prostate cancer (P = 0.004), higher Gleason scores (P = 0.004), and higher stages in men undergoing a radical prostatectomy (P = 0.011). Both the Mdm4 and Hausp SNPs (rs1380576 and rs1529916) were found to be associated with higher D'Amico risk prostate cancer category at the time of diagnosis (P = 0.023 and P = 0.046, respectively). Mdm4 SNP was also found to be associated with higher Gleason score at radical prostatectomy (P = 0.047). We did not observe any statistically significant association between the p53 Arg72Pro polymorphism and prostate cancer aggressiveness or pathologic variables.
CONCLUSIONS: These results suggested the importance of these p53 regulators in prostate cancer development and progression. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20855462      PMCID: PMC2970725          DOI: 10.1158/1078-0432.CCR-10-1261

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  36 in total

1.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

3.  p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer.

Authors:  Shu-Pin Huang; Wen-Jeng Wu; Wun-Shaing Wayne Chang; Ming-Tsang Wu; Yun-Yun Chen; Yun-Ju Chen; Chia-Cheng Yu; Tony T Wu; Ying-Huei Lee; Jong-Khing Huang; Chun-Hsiung Huang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-12       Impact factor: 4.254

4.  Association of codon 72 polymorphism of p53 with lower prostate cancer risk.

Authors:  W D Henner; A J Evans; K M Hough; E L Harris; B A Lowe; T M Beer
Journal:  Prostate       Date:  2001-12-01       Impact factor: 4.104

5.  Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; D Schultz; M Loffredo; R Dugal; M Hurwitz; I Kaplan; C J Beard; A A Renshaw; P W Kantoff
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

6.  Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells.

Authors:  M Burchardt; T Burchardt; A Shabsigh; M Ghafar; M W Chen; A Anastasiadis; A de la Taille; A Kiss; R Buttyan
Journal:  Prostate       Date:  2001-09-15       Impact factor: 4.104

7.  A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Authors:  Gareth L Bond; Wenwei Hu; Elisabeth E Bond; Harlan Robins; Stuart G Lutzker; Nicoleta C Arva; Jill Bargonetti; Frank Bartel; Helge Taubert; Peter Wuerl; Kenan Onel; Linwah Yip; Shih-Jen Hwang; Louise C Strong; Guillermina Lozano; Arnold J Levine
Journal:  Cell       Date:  2004-11-24       Impact factor: 41.582

8.  Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase.

Authors:  Hui-Kuan Lin; Liang Wang; Yueh-Chiang Hu; Saleh Altuwaijri; Chawnshang Chang
Journal:  EMBO J       Date:  2002-08-01       Impact factor: 11.598

9.  A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese.

Authors:  Kazuhiro Suzuki; Hiroshi Matsui; Nobuaki Ohtake; Seiji Nakata; Tomoyuki Takei; Haruki Nakazato; Hironobu Okugi; Hidekazu Koike; Yoshihiro Ono; Kazuto Ito; Kohei Kurokawa; Hidetoshi Yamanaka
Journal:  J Biomed Sci       Date:  2003 Jul-Aug       Impact factor: 8.410

10.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential.

Authors:  Patrick Dumont; J I-Ju Leu; Anthony C Della Pietra; Donna L George; Maureen Murphy
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

View more
  18 in total

1.  A genetic variant within MDM4 3'UTR miRNA binding site is associated with HPV16-positive tumors and survival of oropharyngeal cancer.

Authors:  Yang Zhang; Erich M Sturgis; Peng Wei; Hongliang Liu; Ziqiao Wang; Yiding Ma; Chuan Liu; Kyle J Gu; Qingyi Wei; Guojun Li
Journal:  Mol Carcinog       Date:  2019-09-12       Impact factor: 4.784

2.  Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.

Authors:  Jeannette T Bensen; Zongli Xu; Gary J Smith; James L Mohler; Elizabeth T H Fontham; Jack A Taylor
Journal:  Prostate       Date:  2012-05-01       Impact factor: 4.104

3.  MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.

Authors:  Han Zhao; Yu-Zhuo Xie; Rui Xing; Ming Sun; Feng Chi; Yue-Can Zeng
Journal:  Cell Oncol (Dordr)       Date:  2017-05-31       Impact factor: 6.730

4.  The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis.

Authors:  Jie Yang; Wen Gao; Ning-Hong Song; Wei Wang; Jie-Xiu Zhang; Pei Lu; Li-Xin Hua; Min Gu
Journal:  Asian J Androl       Date:  2012-08-20       Impact factor: 3.285

5.  Association of p53 and p21 polymorphisms with prostate cancer.

Authors:  Monika Kmeťová Sivoňová; Marta Vilčková; Ján Kliment; Silvia Mahmood; Jana Jurečeková; Svetlana Dušenková; Iveta Waczulíková; Peter Slezák; Dušan Dobrota
Journal:  Biomed Rep       Date:  2015-07-27

6.  Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck.

Authors:  Lei Jin; Erich M Sturgis; Yang Zhang; Zhigang Huang; Peng Wei; Wei Guo; Zhongqiu Wang; Qingyi Wei; Xicheng Song; Guojun Li
Journal:  Carcinogenesis       Date:  2013-03-18       Impact factor: 4.944

Review 7.  Genetic Modifiers of the p53 Pathway.

Authors:  Subhasree Basu; Maureen E Murphy
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

8.  Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx.

Authors:  Zhongming Lu; Erich M Sturgis; Lijun Zhu; Hua Zhang; Ye Tao; Peng Wei; Qingyi Wei; Guojun Li
Journal:  Mol Carcinog       Date:  2017-11-13       Impact factor: 4.784

9.  Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer.

Authors:  Seema Sethi; Dejuan Kong; Sue Land; Gregory Dyson; Wael A Sakr; Fazlul H Sarkar
Journal:  Am J Transl Res       Date:  2013-03-28       Impact factor: 4.060

10.  Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.

Authors:  Rosalind A Eeles; Ali Amin Al Olama; Sara Benlloch; Edward J Saunders; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Maya Ghoussaini; Craig Luccarini; Joe Dennis; Sarah Jugurnauth-Little; Tokhir Dadaev; David E Neal; Freddie C Hamdy; Jenny L Donovan; Ken Muir; Graham G Giles; Gianluca Severi; Fredrik Wiklund; Henrik Gronberg; Christopher A Haiman; Fredrick Schumacher; Brian E Henderson; Loic Le Marchand; Sara Lindstrom; Peter Kraft; David J Hunter; Susan Gapstur; Stephen J Chanock; Sonja I Berndt; Demetrius Albanes; Gerald Andriole; Johanna Schleutker; Maren Weischer; Federico Canzian; Elio Riboli; Tim J Key; Ruth C Travis; Daniele Campa; Sue A Ingles; Esther M John; Richard B Hayes; Paul D P Pharoah; Nora Pashayan; Kay-Tee Khaw; Janet L Stanford; Elaine A Ostrander; Lisa B Signorello; Stephen N Thibodeau; Dan Schaid; Christiane Maier; Walther Vogel; Adam S Kibel; Cezary Cybulski; Jan Lubinski; Lisa Cannon-Albright; Hermann Brenner; Jong Y Park; Radka Kaneva; Jyotsna Batra; Amanda B Spurdle; Judith A Clements; Manuel R Teixeira; Ed Dicks; Andrew Lee; Alison M Dunning; Caroline Baynes; Don Conroy; Melanie J Maranian; Shahana Ahmed; Koveela Govindasami; Michelle Guy; Rosemary A Wilkinson; Emma J Sawyer; Angela Morgan; David P Dearnaley; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Nicholas J Van As; Christopher J Woodhouse; Alan Thompson; Tim Dudderidge; Chris Ogden; Colin S Cooper; Artitaya Lophatananon; Angela Cox; Melissa C Southey; John L Hopper; Dallas R English; Markus Aly; Jan Adolfsson; Jiangfeng Xu; Siqun L Zheng; Meredith Yeager; Rudolf Kaaks; W Ryan Diver; Mia M Gaudet; Mariana C Stern; Roman Corral; Amit D Joshi; Ahva Shahabi; Tiina Wahlfors; Teuvo L J Tammela; Anssi Auvinen; Jarmo Virtamo; Peter Klarskov; Børge G Nordestgaard; M Andreas Røder; Sune F Nielsen; Stig E Bojesen; Afshan Siddiq; Liesel M Fitzgerald; Suzanne Kolb; Erika M Kwon; Danielle M Karyadi; William J Blot; Wei Zheng; Qiuyin Cai; Shannon K McDonnell; Antje E Rinckleb; Bettina Drake; Graham Colditz; Dominika Wokolorczyk; Robert A Stephenson; Craig Teerlink; Heiko Muller; Dietrich Rothenbacher; Thomas A Sellers; Hui-Yi Lin; Chavdar Slavov; Vanio Mitev; Felicity Lose; Srilakshmi Srinivasan; Sofia Maia; Paula Paulo; Ethan Lange; Kathleen A Cooney; Antonis C Antoniou; Daniel Vincent; François Bacot; Daniel C Tessier; Zsofia Kote-Jarai; Douglas F Easton
Journal:  Nat Genet       Date:  2013-04       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.